Medpace Holdings (MEDP)

As of 30 September 2026, short interest in MEDP is 1,596,293 shares, down 74,402 shares over the last month. Over the last 48 readings it ranged from 1,004,376 shares (15 January 2025) to 3,265,067 shares (30 June 2025). At the reported average volume of 275K shares a day that is 5.8 days to cover.

<iframe src="https://xoomar.com/embed/stocks/medp" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of MEDP volume is 54.9%, up 2.0 points over the last five sessions. Over the last 30 readings it ranged from 40.6% (7 October 2026) to 66.3% (8 September 2026). The latest reading is in line with the 30-session average of 54.7%, on 68K shares reported.

As of 4 September 2026, the fails-to-deliver balance in MEDP is 2 shares, down 992 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 August 2026) to 31,974 shares (24 July 2026). The latest reading sits at the bottom of that range.

Insiders at MEDP reported 31 open-market sells worth $208.5M in the last 90 days and no open-market buys. Latest filing: BURWIG SUSAN E (Exec. VP, Operations) on 2026-10-07.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

25 Form 144 notices on file for MEDP worth $492.0M at the prices reported; 11 in the last 90 days worth $218.7M. Latest: Kraft Robert O. filed on 2026-08-26 to sell 3,858 shares ($2.4M) from 2026-08-26.

3 holders report 5% or more of MEDP in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is August J. Troendle at 19.1% of the class (5,396,508 shares), filed 2026-09-28 for an event on 2026-09-24.

6 of the 30 tracked managers held MEDP at their latest 13F, $1.10B in total at quarter-end prices. AQR Capital Management is the largest at $677.3M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 6 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) Medpace Holdings reported revenue of $707.3M, up 17.2% from the same quarter a year earlier, and net income of $121.4M (4.25 diluted EPS). In FY 2025 it generated $713.2M of operating cash flow and spent $917.4M on buybacks.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-17 from the cover page.